Too little too late
may sound pithy, but sounding pithy doesn't make something right.
If the blinded data, which should present the treatment and control arm data together as if this were a single arm trial, is impressively better than any other present GBM data (especially for any approved treatment like the electronic helmet one, who's current median OS for their treatment patients indicates 20 months), then the market should realize that the unblinded data for DCVax-L will trend even higher for their treatment arm.
That alone should impress the market.
Ultimately, the purpose for those in the market is to make money. Once the market realizes it can make money in $NWBO... with a P3 trial for GBM based on information indicating efficacy, albeit by non-traditional fundamentals (blinded, blended data for now), the market will begin
to pile in, especially at these pathetically low prices.
And if there is a large naked short contingency, they will ultimately be forced to correct. If there's not, then $NWBO will rise more slowly on its own momentum.
And let's not forget the GMB patients in this tale.
If someone is diagnosed with GBM and they google their cancer and this abstract for DCVax-L pops up indicating perhaps really good blinded data... data that may be music to their ears, these patients and their families will start converging on the FDA demanding quick approval.
So I'll end this post with something tasty to chew on, and that is "it's hard to hide something everyone is looking for."